Premium
RECOMBINANT HUMAN INTERLEUKIN‐6 ENHANCES THE ANTIPROLIFERATION AND DIFFERENTIATION INDUCING EFFECTS OF RETINOIC ACID IN HL‐60 HUMAN MYELOID LEUKAEMIC CELLS
Author(s) -
Hassan H. T.
Publication year - 1991
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1991.tb01405.x
Subject(s) - retinoic acid , myeloid , tretinoin , retinoic acid receptor beta , cancer research , interleukin , retinoic acid inducible orphan g protein coupled receptor , interleukin 3 , cell culture , chemistry , immunology , retinoic acid receptor , biology , medicine , pharmacology , cytokine , t cell , immune system , interleukin 21 , genetics
SUMMARY 1. The effect of recombinant human interleukin‐6 on the antiproliferation and differentiation inducing actions of all‐trans retinoic acid in HL‐60 human myeloid leukaemia cells was studied in short‐term liquid suspension culture. 2. Interleukin‐6 alone showed no significant effect on HL‐60 human myeloid leukaemia cells. 3. The addition of interleukin‐6 to all‐trans retinoic acid‐treated cultures of HL‐60 human myeloid leukaemia cells significantly enhanced the desired antiproliferation effect of all‐trans retinoic acid. 4. The combination of interleukin‐6 with all‐trans retinoic acid reduced the doses of all‐trans retinoic acid required to induce the same differentiation of HL‐60 cells as single agent by between 1.7‐ and 4.8‐fold; that is, the efficacy of all‐trans retinoic acid in inducing the differentiation of human myeloid leukaemia HL‐60 cells was increased up to 4.8 times by its combination with interleukin‐6. 5. The combination of all‐trans retinoic acid and interleukin‐6 could provide an effective alternative therapy for elderly myeloid leukaemia patients.